Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  New England Journal of Medicine

• Publication date

  2009-12-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa0908492PMID 19843557
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

  2010cited by this paper
• IMPACT OF THAILAND'S HIV-CONTROL PROGRAMME AS INDICATED BY THE DECLINE OF SEXUALLY TRANSMITTED DISEASES

  2010cited by this paper
• Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection

  2009cited by this paper
• The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection

  2009cited by this paper
• T-cell quality in memory and protection: implications for vaccine design

  2008cited by this paper
• HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

  2008cited by this paper
• Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

  2008cited by this paper
• Recombinant gp120 Vaccine-Induced Antibodies Inhibit Clinical Strains of HIV-1 in the Presence of Fc Receptor-Bearing Effector Cells and Correlate Inversely with HIV Infection Rate1

  2007cited by this paper
• Evaluation of Cellular Immune Responses in Subjects Chronically Infected with HIV Type 1

  2007cited by this paper
• Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120: Negative Results Fail to Trigger a Phase 3 Correlates Trial

  2007cited by this paper
• Acceptability of A-CASI by HIV-Positive IDUs in a Multisite, Randomized, Controlled Trial of Behavioral Intervention (INSPIRE)

  2007cited by this paper
• A Phase 1/2 Comparative Vaccine Trial of the Safety and Immunogenicity of a CRF01_AE (Subtype E) Candidate Vaccine: ALVAC-HIV (vCP1521) Prime With Oligomeric gp160 (92TH023/LAI-DID) or Bivalent gp120 (CM235/SF2) Boost

  2007cited by this paper
• Evolution of innate and adaptive effector cell functions during acute HIV-1 infection.

  2007cited by this paper
• HIV/AIDS preventive vaccine ‘prime-boost’ phase III trial: foundations and initial lessons learned from Thailand

  2006cited by this paper
• Placebocontrolled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV-1 InfectionGurwith M, for the rgp 120 HIV Vaccine Study Group (VaxGen, Brisbane, Calif; et al) J Infect Dis 191:654–665, 2005§

  2006cited by this paper
• Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

  2006cited by this paper
• Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4+ T-Cell Loss and Reduces both Systemic and Mucosal Simian-Human Immunodeficiency Virus SHIVKU2 RNA Levels

  2006cited by this paper
• HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.

  2005cited by this paper
• Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand.

  2005cited by this paper
• Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

  2005cited by this paper
• Attenuated Poxvirus-Based Simian Immunodeficiency Virus (SIV) Vaccines Given in Infancy Partially Protect Infant and Juvenile Macaques Against Repeated Oral Challenge With Virulent SIV

  2005cited by this paper
• Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines

  2005cited by this paper
• Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

  2005cited by this paper
• Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.

  2004cited by this paper
• Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.

  2004cited by this paper
• The Asian Epidemic Model: a process model for exploring HIV policy and programme alternatives in Asia

  2004cited by this paper
• Phase I/II Study of a Candidate Vaccine Designed Against the B and E Subtypes of HIV-1

  2004cited by this paper
• Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.

  2003cited by this paper
• Comparison Between Env-Specific T-Cell Epitopic Responses in HIV-1-Uninfected Adults Immunized with Combination of ALVAC-HIV(vCP205) Plus or Minus rgp160MN/LAI-2 and HIV-1-Infected Adults

  2003cited by this paper
• Sensitivity Analysis for the Assessment of Causal Vaccine Effects on Viral Load in HIV Vaccine Trials

  2003cited by this paper
• A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays.

  2002cited by this paper
• Safety and Immunogenicity of a High‐Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV‐1‐Uninfected Adults: AIDS Vaccine Evaluation Group Protocol 022A

  2002cited by this paper
• ALVAC-SIV-gag-pol-env-Based Vaccination and Macaque Major Histocompatibility Complex Class I (A*01) Delay Simian Immunodeficiency Virus SIVmac-Induced Immunodeficiency

  2002cited by this paper
• Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.

  2001cited by this paper
• Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

  2001cited by this paper
• A Human Immunodeficiency Virus Prime-Boost Immunization Regimen in Humans Induces Antibodies That Show Interclade Cross-Reactivity and Neutralize Several X4-, R5-, and Dualtropic Clade B and C Primary Isolates

  2000cited by this paper
• A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais.

  2000cited by this paper
• A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences.

  2000cited by this paper
• HIV/AIDS prevention in Thailand: success and challenges.

  1998cited by this paper
• Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate HIV vaccines.

  1998cited by this paper
• Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.

  1998cited by this paper
• Preventive HIV vaccine development in Thailand.

  1998cited by this paper
• Induction of immune responses to HIV‐1 by canarypox virus (ALVAC) HIV‐1 and gp120 SF‐2 recombinant vaccines in uninfected volunteers

  1998cited by this paper
• Changes in sexual behavior and a decline in HIV infection among young men in Thailand.

  1996cited by this paper
• Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

  1996cited by this paper
• Impact of Thailand's HIV-control programme as indicated by the decline of sexually transmitted diseases.

  1994cited by this paper
• Neutralizing Antibodies to HIV-1 in Seronegative Volunteers Immunized With Recombinant gp 120 From the MN Strain of HIV-1

  1994cited by this paper
• Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.

  1994cited by this paper
• Risk factors for HIV infection among young adult men in northern Thailand.

  1993cited by this paper
• The epidemiology of HIV infection and AIDS in Thailand.

  1991cited by this paper
• The epidemiology of HIV infection and AIDS

  1990cited by this paper
• Trial in Thailand

  1974cited by this paper

• Harnessing mucosal immunity for protective vaccines.

  2026cites this paper
• Intranasal Delivery of HIV/SIV Antigens with NE/AS01B Adjuvants Enhances Cellular Immunity and Reduces Viral Loads in SHIV-Challenged Macaques

  2026cites this paper
• Broadening SARS-CoV-2 Immunity by Combining ORFV and Protein-Based Vaccines

  2026cites this paper
• Immunogenicity and protection mediated by dmLT and alum adjuvants for an HIV-1 vaccine

  2026cites this paper
• Viral glycoprotein-mediated entry and antibody-mediated immunity in HIV-1 and SARS-CoV-2 infection

  2026cites this paper
• Understanding the performance of HIV-1 viral vector vaccines: adenovirus and poxvirus case studies

  2026cites this paper
• Dissecting the steps in early simian immunodeficiency virus dissemination following mucosal and intravenous infection of rhesus macaques

  2026cites this paper
• Divalent HIV-1 gp120 Immunogen Exhibits Selective Avidity for Broadly Neutralizing Antibody VRC01 Precursors

  2026cites this paper
• From outbreak to breakthrough: Scientific and technological advances in control and cure HIV/AIDS

  2025cites this paper
• Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity

  2025cites this paper
• ALFQ adjuvanted HIV-1 envelope protein vaccination elicits durable functional antibody and cellular responses in nonhuman primates

  2025cites this paper
• Reduced Fc-mediated antibody responses after COVID-19 mRNA vaccination in a cohort of people living with HIV-1

  2025cites this paper
• Endocervix exhibits greater susceptibility to HIV-1 infection compared to ectocervix following ex vivo exposure to Transmitted/Founder HIV-1 variants

  2025cites this paper
• A viral vector prime and protein boost vaccine regimen elicits higher binding antibody titers than a homologous viral vector prime-boost regimen

  2025cites this paper
• Losing Less in Translation: Relating the Preclinical Evidence Base for Active and Passive Immunity to Prevention of HIV‐1 Infection in Humans

  2025cites this paper
• HIV vaccine - Is there a ray of hope in the rugged journey?

  2025cites this paper
• Effects of Test-and-Treat versus PrEP on elimination of HIV transmission: analysis of 24 HIV prevention trials.

  2025cites this paper
• Safety and immunogenicity of an HIV vaccine trial with DNA prime and replicating vaccinia boost

  2025cites this paper
• Novel oral adjuvant to enhance cytotoxic memory like NK cell responses in HIV vaccine platform

  2025influential citation
• Inclusion of a retroviral protease enhances the immunogenicity of VLP-forming mRNA vaccines against HIV-1 or SARS-CoV-2 in mice

  2025cites this paper
• Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis

  2025cites this paper
• System vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humans

  2025cites this paper
• Accelerating vaccine development in Africa: lessons from HIV research.

  2025cites this paper
• Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans.

  2025cites this paper
• Targeting Langerhans cells via skin delivery of HIV Envelope enhances the antibody response to vaccination

  2025cites this paper
• Evaluating the Immune Response in Rabbits to an Escalating Dose of mRNA-Based HIV-1 Env Immunogens

  2025cites this paper
• Understanding mechanistic relationships between IgG titers and Fc effector functions: a computational framework to assess polyfunctionality

  2025cites this paper
• Candidate correlates of protection in the HVTN505 HIV-1 vaccine efficacy trial identified by positive-unlabeled learning

  2025cites this paper
• HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques

  2025cites this paper
• Building a better natural killer (NK) cell: Fc receptor engineering strategies for NK cell therapeutics.

  2025cites this paper
• Targeting HIV-1 immune escape mechanisms: Key advances and challenges in HIV-1 vaccine design.

  2025cites this paper
• A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials

  2025influential citation
• Heterologous combinations of VSV-GP and native-like trimers elicit autologous Tier 2 HIV antibodies in rabbits

  2025cites this paper
• Divalent HIV-1 gp120 Immunogen Exhibits Selective Avidity for Broadly Neutralizing Antibody VRC01 Precursors

  2025cites this paper
• Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity

  2025cites this paper
• Multiple Mechanisms of HIV-1 Resistance to PGT135 in a Chinese Subtype B’ Slow Progressor

  2025cites this paper
• Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa

  2025cites this paper
• Transient pain and long-term gain: adjuvant dose directs immune memory

  2025cites this paper
• Deciphering HIV vaccine-induced antibody response according to ethnicity

  2025cites this paper
• An early functional adaptive NK cell signature drives optimal CD8+ T-cell activation and predicts sustained HIV-1 viral control

  2025cites this paper
• ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost

  2025cites this paper
• More antibodies are not always better: Fc effector functions play a critical role in SARS-CoV-2 infection and protection.

  2025cites this paper
• Progress and Recent Developments in HIV Vaccine Research

  2025cites this paper
• Navigating the Complexities of HIV Vaccine Development: Lessons from the Mosaico Trial and Next-Generation Development Strategies

  2025cites this paper
• Computationally Selected Multivalent HIV-1 Subtype C Vaccine Protects Against Heterologous SHIV Challenge

  2025cites this paper
• mRNA-based vaccines and therapies - a revolutionary approach for conquering fast-spreading infections and other clinical applications: a review.

  2025cites this paper
• Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial.

  2025cites this paper
• Intérêt et limites des corrélats immunologiques de protection

  2025cites this paper
• Update on HIV Chemoprevention.

  2025cites this paper
• Effects and mechanisms of monoclonal and polyclonal human antibodies in protection of humanized mice from HIV-1 challenge

  2025cites this paper
• Enhancing functional antibody responses against HIV envelope V1V2 through vaccine formulations

  2025cites this paper
• High peak viraemia followed by spontaneous HIV‐1 control in women living with HIV‐1 subtype A1 in East Africa

  2025cites this paper
• Poxvirus Vectors Activate Human NK and MAIT Cells in a Type I Interferon, IL-18, and Monocyte-Dependent Manner

  2025cites this paper
• Unveiling an Immunological Mystery: Deciphering the Durability Divide in Vaccine-Elicited Antibody Responses.

  2025cites this paper
• Accelerated cGMP production of near-native HIV-1 Env trimers following electroporation transfection and immunogenicity analysis

  2025cites this paper
• A unified protocol chatbot reduces anxiety by encouraging university students’ negative emotional expressions: A randomized controlled trial

  2025cites this paper
• Harnessing innate immunity: natural killer cells and innate immune responses in reservoir clearance

  2025cites this paper
• Online Conference “Chronic Viral Infections and Cancer, Openings for Vaccines and Cure” VIRCAN2024, Monitoring the Progress

  2025cites this paper
• Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand.

  2025cites this paper
• Effects of sex but not race and geographic origin on vaccine-induced HIV-specific antibody responses

  2025cites this paper
• Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG

  2024influential citation
• Proteomic analysis of plasma in healthy adults receiving recombinant vaccinia virus provides novel insights into HIV‐1 neutralizing antibodies

  2024cites this paper
• Human Immunodeficiency Virus Vaccine: Promise and Challenges.

  2024cites this paper
• Making a Monkey out of Human Immunodeficiency Virus/Simian Immunodeficiency Virus Pathogenesis: Immune Cell Depletion Experiments as a Tool to Understand the Immune Correlates of Protection and Pathogenicity in HIV Infection

  2024cites this paper
• Broadly neutralizing antibodies and monoclonal V2 antibodies derived from RV305 inhibit capture and replication of HIV-1.

  2024cites this paper
• Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial

  2024cites this paper
• Multi-omics analysis reveals the dynamic interplay between Vero host chromatin structure and function during vaccinia virus infection

  2024cites this paper
• Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives

  2024cites this paper
• Opportunities and challenges for T cell-based influenza vaccines

  2024cites this paper
• The Question of HIV Vaccine: Why Is a Solution Not Yet Available?

  2024influential citation
• SWIFT clustering analysis of intracellular cytokine staining flow cytometry data of the HVTN 105 vaccine trial reveals high frequencies of HIV-specific CD4+ T cell responses and associations with humoral responses

  2024cites this paper
• Innate protection against intrarectal SIV acquisition by a live SHIV vaccine

  2024cites this paper
• Modelling Role of Protective and Nonprotective HLA Allele Inducing Different HIV Infection Outcomes

  2024cites this paper
• Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention

  2024cites this paper
• HIV-1 Gag, Pol, and Env diversified with limited adaptation since the 1980s

  2024cites this paper
• Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial

  2024cites this paper
• Viral therapy for targeted drug delivery to cancers: Recent advances, clinical and regulatory perspectives

  2024cites this paper
• Impact of Recombinant VSV-HIV Prime, DNA-Boost Vaccine Candidates on Immunogenicity and Viremia on SHIV-Infected Rhesus Macaques

  2024cites this paper
• Contralateral second dose improves antibody responses to a 2-dose mRNA vaccination regimen

  2024influential citation
• Perceptions and Acceptance of a Prophylactic Vaccine for Human Immunodeficiency Virus (HIV): A Qualitative Study

  2024cites this paper
• Genetic Code Expansion: Recent Developments and Emerging Applications

  2024cites this paper
• Optimizing encephalomyocarditis virus VP1 protein assembly on pseudorabies virus envelope via US9 protein anchoring

  2024cites this paper
• Politics of HIV Vaccine Research from International to Global Health

  2024cites this paper
• Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific response

  2024cites this paper
• Different immunogens and prime-boost vaccination strategies affect the efficacy of recombinant candidate vaccines against pathogenic orthopoxviruses

  2024cites this paper
• Comparing HIV Vaccine Immunogenicity across Trials with Different Populations and Study Designs

  2024cites this paper
• Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06)

  2024cites this paper
• Negative Control Outcome Adjustment in Early‐Phase Randomized Trials: Estimating Vaccine Effects on Immune Responses in HIV Exposed Uninfected Infants

  2024cites this paper
• Signal peptide exchange alters HIV-1 envelope antigenicity and immunogenicity

  2024cites this paper
• Potent antibody-dependent cellular cytotoxicity of a V2-specific antibody is not sufficient for protection of macaques against SIV challenge

  2024cites this paper
• Unpredicted Protective Function of Fc-Mediated Inhibitory Antibodies for HIV and SARS-CoV-2 Vaccines

  2024influential citation
• Positive-unlabeled learning to infer protection status and identify correlates in vaccine efficacy field trials

  2024cites this paper
• Innate immune cell activation after HIV-1 vaccine administration is associated with increased antibody production

  2024cites this paper
• Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects

  2024cites this paper
• Mosaic HIV-1 vaccine and SHIV challenge strain V2 loop sequence identity and protection in primates

  2024cites this paper
• Mechanisms and Implications of IgG4 Responses to SARS-CoV-2 and Other Repeatedly Administered Vaccines.

  2024cites this paper
• DNA and protein HIV vaccines: how should we mix it?

  2024cites this paper
• Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.

  2024cites this paper
• Contemporary HIV-1 consensus Env with AI-assisted redesigned hypervariable loops promote antibody binding

  2024cites this paper
• Clinical trials and recent progress in HIV vaccine development

  2024cites this paper